Articles related to HEALTHCARE ACCESS

FDA approval of first at-home cervical cancer screening device represents significant advancement in accessible cancer prevention, requiring structured clinical integration protocols.

MHNP representation in mental health visits increased from 12.5% to 29.8% between 2011-2019, with rural areas showing particularly dramatic adoption rates exceeding 50% in full-scope practice states.

Four NP-owned practices demonstrate how autonomy, clinical excellence, and community engagement converge in grassroots models that reshape access and outcomes in underserved areas.

Medicare reimbursement for RPM remains lowest in rural areas where chronic disease prevalence exceeds national averages and provider access presents significant challenges.

Patients report significant weight loss with compounded semaglutide that would be difficult to maintain if forced to discontinue treatment due to cost barriers, despite manufacturer discount programs reducing brand-name medication costs to approximately $499 monthly.

A Lilly spokesperson told Verywell that about 10% of people who start taking Zepbound for the first time enroll in the self-pay program. This includes people who previously used compounded tirzepatide.